How to Use Non-Dilutive Funding for Peptide R&D: A Step-by-Step Outsourcing Guide

What counts as non-dilutive funding for peptide R&D, and which programs actually fit?

Qhov cai haum yog yooj yim: sib phim qhov kev pab cuam rau qib pov thawj uas koj twb tuaj yeem qhia tau, tsis phim qhov loj ntawm nyiaj pab. Cov Kev Pab Lag Luam Me Me ntawm NIH tau npaj ua theem, thiab qhov NIH Grants Policy Statement's SBIR/STTR tshooj piav qhia lawv: Theem I qhia txog qhov muaj txiaj ntsig thiab qhov ua tau ntawm kev tshawb fawb thiab qhov zoo ntawm tus neeg thov kev ua haujlwm, thaum Theem II txuas ntxiv ua haujlwm ntawd thiab tau nyiaj txiag raws li cov txiaj ntsig ntawm Theem I thiab kev txawj ntse thiab kev lag luam ntawm daim ntawv thov Theem II. Qhov seem tib yam no teev ib txoj kev ncaj qha mus rau Theem II rau cov tuam txhab uas twb tau qhia tau tias ua tau yam tsis muaj Theem I rau qhov project ntawd, ib qho khoom plig Phase IIB txuas ntxiv, thiab Commercialization Readiness Pilot rau kev tsim kho tom qab.

Cov kev pab cuam hauv xeev puv qhov chaw hauv qab thiab ib sab ntawm cov theem federal. s Massachusetts Life Sciences Center's Access and Accelerate grant cov khoom plig feem ntau $75,000 to $100,000 thiab tsis pub tshaj $150,000, tso tawm 80% thaum ua tiav thiab 20% thaum them rov qab, khiav txhua peb hlis, thiab tej zaum yuav muab qhov tseem ceeb rau cov tau txais SBIR/STTR yam tsis tas yuav tau txais khoom plig. s Life Sciences Center's Impact Catalyst program muab mus txog $250,000 them nyiaj 25% / 25% / 50% raws li cov milestones, thiab yuav tsum muaj ib lub hauv paus hauv Massachusetts uas muaj ntau tshaj qhov tseem ceeb 50% ntawm cov neeg ua haujlwm hauv Massachusetts ntxiv rau ib qho kev sib tw nrog cov neeg nqis peev mob siab. Cov xwm txheej nyob thiab cov neeg nqis peev yog qhov laj thawj uas ib qho nyiaj pab tsoomfwv tsis yog qhov yooj yim tshaj plaws; lawv yog ib qho kev ntsuam xyuas tsim nyog txawv.

The NIH figures are guideline budgets for the current cycle, luam tawm rau NIH’s Peptide Pegylation Manufacturer own walkthrough of the SBIR and STTR phases; individual institutes and centers can set their own limits, and the active notice of funding opportunity governs.

How do SBIR/STTR phase structure and work-share rules constrain how much peptide work I can outsource?

Nmp Peptide Synthesis The work-share rule is the first constraint on outsourcing peptide synthesis for grant-funded projects, and it is stated from two directions that mean the same thing. s official SBIR program FAQ states that in Phase I the proposing firm must perform a minimum of two-thirds of the research or analytical effort, with one third subcontractable to another firm or research organization, and that in Phase II the firm must perform a minimum of one-half. NIH’s program page expresses the Phase I rule from the other end, as small businesses outsourcing 33% of Phase I research. Two-thirds performed and one-third outsourced are the same arithmetic.

For STTR, the small business and a single qualifying research institution must meet their respective minimum work shares under the applicable directive. The commonly cited 40% thiab 30% minima leave at most 30% for others; they do not require a fixed 40/30/30 allocation. Confirm the agency’s effort calculation, eligible participants and active solicitation.

That measurement choice is the practical trap. If your solicitation measures effort in labor hours, a peptide synthesis invoice does not consume your outsourceable share the way you might assume; if it measures in total award dollars, every outsourced dollar counts against the fraction. Read the measurement sentence in your solicitation before you size the vendor scope.

How do I turn a scientific uncertainty into a milestone a review panel can verify?

Map the uncertainty to an achieved outcome with a number in it. NINDS’s published milestone examples are written as achieved outcomes, each tagged with a completion timeframe and carrying quantitative success criteria and go/no-go logic, rather than as activities to be performed. A milestone that reads “synthesize and characterize the modified peptide” describes work; a milestone that reads “obtain a lot with ≥95% HPLC purity and confirmed molecular mass by the end of month 6, with a go/no-go decision on scale-up” describes a result a reviewer can check against a document.

The phase definition tells you how far the milestone may reach. Because the NIH Grants Policy Statement’s SBIR/STTR section frames Phase I as establishing technical merit and feasibility, a Phase I milestone should prove that a difficult sequence can be made and measured, not that a manufacturing route is validated. Feasibility evidence is not development readiness, and no program publishes that rule in those words; the milestone form is the closest published expression of it.

Which outsourced peptide activities belong in which budget line, and what does each line justify?

The budget line follows the nature of the work, not the name of the vendor. NSF’s SBIR budget instructions place specialized work by non-employees in G.3 Consultant Services, subawards in G.5 when a significant portion of the work will be performed by another organization and the work is not widely commercially available, and the purchase of technical and R&D services from commercial sources in G.6 Other Direct Costs, naming analytical and testing services as a typical cost. The same instructions cap the consulting daily rate at $1,000 per eight-hour day, require a signed Letter of Commitment for consultants, and require subawards to carry a separate budget and justification in the same format as the main budget.

On the NIH side, NIH SBIR/STTR cov lus qhia thov hais tias F.5 npog tag nrho cov koom haum subaward thiab consortium thiab lwm yam nqi kev cog lus, suav nrog ob qho nqi ncaj qha thiab tsis ncaj qha, thiab tias cov nqi cog lus rau kev pab txhawb xws li kev kuaj hauv lub koom haum ntawm cov khoom biological tej zaum yuav tsum tau faib meej hauv Tshooj L. NIH cov lus qhia nyiaj txiag rau cov neeg thov ntxiv tias cov kws pab tswv yim yuav tsum nyob hauv F.3 es tsis yog hauv pawg neeg ua haujlwm tseem ceeb yog tias lawv tsis yog cov neeg ua haujlwm ntawm lub koom haum thov, thiab txhua consortium yuav tsum muaj nws tus kheej daim ntawv nyiaj txiag.

Line numbers follow the agency forms and the active solicitation, so confirm them against the forms package you are actually submitting.

What documents will my peptide supplier actually issue, and which ones can a reviewer check?

A claim about a lot rests on that lot’s own certificate of analysis, chromatogram and mass-spectrometry data, and the reviewer checks the analytical method behind them. ICH Q2(R2), adopted November 2023, sets out in Table 1 which validation parameters each analytical purpose requires: identity requires specificity or selectivity only; a quantitative impurity (purity) determination requires specificity, x, qhov txwv qis dua (quantitation limit and detection limit), kev raug thiab qhov tseeb; a limit test requires specificity and detection capability; and an assay for content or potency requires specificity, x, kev raug thiab qhov tseeb. That table tells you which evidence to buy for the milestone you claimed. A purity milestone needs the full purity row; an identity confirmation milestone does not.

Electronic records carry their own requirements. 21 CFR Part 11 applies to electronic records created, modified, maintained, archived, retrieved or transmitted under any agency records requirement, and to electronic records submitted to the agency under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and it requires that computer systems, controls and attendant documentation be readily available for, and subject to, FDA inspection. For a peptide intended for a parenteral route, USP <85> is the harmonized bacterial endotoxins chapter, official since 1 December 2012, and it is the reference a reviewer will recognize for the endotoxin field. No regulator publishes a peptide certificate-of-analysis template, so the field list a reviewer expects is assembled from these anchors plus the supplier’s own method documentation.

Where must my readiness claims stop when describing planned versus demonstrated work?

The line sits between what a document in your application proves and what it promises. A feasibility lot with a certificate of analysis proves that a sequence was made and measured; nws tsis pov thawj tias txheej txheem rov ua tau ntawm lwm qib, thiab nws tsis pov thawj tias kev hloov kho tom qab yuav ua haujlwm ntawm tib lub scaffolding. NINDS’s published milestone examples qhia lo lus nyab xeeb: txhua kauj ruam qhia txog qhov tau ua tiav nrog lub sijhawm ua tiav thiab ib qho go/no-go gate, uas khaws daim ntawv thov nyob hauv lub sijhawm uas txoj haujlwm tau them nyiaj.

Where the evidence stops, hais li ntawd hauv daim ntawv thov. Tsis muaj kev pab cuam twg luam tawm ib qho cai meej uas cais 'yuav qhia' thiab 'tau qhia' hauv zaj dab neeg kev lag luam, yog li kev tswj hwm yuav tsum los ntawm cov lus piav qhia theem thiab hom milestone es tsis yog los ntawm ib qho cai hais txog. Yog tias koj cov ntaub ntawv tsuas yog ib qho kev khiav tshuaj xyuas xwb, piav qhia nws ua ib qho kev khiav tshuaj xyuas ib zaug thiab muab lo lus nug rov ua dua rau hauv lub ntsiab lus tom ntej. Reviewers read overstated readiness as a risk, and the correction costs more than the caution.

How do I choose and brief a peptide partner so the analytical documentation holds up?

Brief the partner on the milestone, not on the sequence alone. A peptide modification and labeling work package brief should name the analytical purpose the milestone depends on, because ICH Q2(R2), adopted November 2023, ties the required validation parameters to that purpose, and a supplier who knows whether you need a purity determination or an identity confirmation will quote the right testing. The brief should also state the lot-level records you expect to receive, since 21 CFR Part 11 governs the electronic records a supplier maintains and makes them subject to inspection.

Continuity across vendors is where documentation usually breaks. If synthesis, modification and analytical testing sit with three suppliers, the analytical method may not transfer, and the reviewer sees three method descriptions instead of one traceable chain. Coordinating synthesis, modification or labeling and analytical testing with one partner, or at minimum fixing the analytical method before the first lot is made, keeps the route from being duplicated and keeps the method identifier consistent across lots. Ask for the method identifier, column, gradient, wavelength and reference standard in the certificate, and confirm the mass-spectrometry ionisation mode, because those are the fields that let a reviewer reproduce the result.

Common mistakes to avoid

The most common mistake is treating the guideline budget figure as the operative one. s NIGMS SBIR page states that NIGMS will not accept applications with budget requests exceeding the statutory budget limitation defined in the specific notice of funding opportunity’s hard cap, except where the project fits an SBA-approved waiver topic, and that applicants considering an over-cap budget should contact the NIGMS SBIR coordinator at least six weeks before the submission due date. The institute and the notice override the guideline.

Three others recur. Placing a synthesis invoice in the wrong line, thaum NSF’s SBIR budget instructions put analytical and testing services in G.6 and subawards in G.5, invites a budget correction. Claiming a purity specification from a supplier’s general marketing page rather than from the lot’s own certificate is the fastest way to lose a reviewer’s confidence, because the specification belongs to the lot. And presenting FDA’s current Q1 stability page as settled guidance misreads its status: that page presents a June 2025 draft consolidated revision, docket FDA-2025-D-1106, marked not for implementation and containing non-binding recommendations, so a stability design should cite the guidance in force and note the consolidation draft separately.

Results: what a fundable, verifiable work package looks like

An assessable package contains a justified milestone, eligible work allocation, supported budget and a plan for traceable evidence. For exploratory peptide work, analytical qualification can be phase-appropriate; a full commercial-release validation package is not automatically required solely because a grant supports the work.

Verify the package by reading it as a reviewer would. For each milestone, name the document that proves it. If a milestone has no document behind it, either the milestone is written as an activity and needs rewriting, or the evidence does not exist yet and the milestone belongs in a later phase. If you want a specification or work package reviewed against these criteria before submission, that review is the natural next step.

Cov lus nug uas tshwm sim ntau zaus

Kuv puas tuaj yeem sib txuas nyiaj pab xeev nrog SBIR lossis STTR nyiaj pab??

Feem ntau yog, provided the two programs fund different costs and neither prohibits concurrent support. The Massachusetts Life Sciences Center’s Access and Accelerate grant gives priority consideration to SBIR/STTR awardees but does not require an award as a condition of eligibility, so a state application can stand on its own. Check the state program’s cost-share language against your federal budget justification before you assume the same line item can be charged twice.

What if my institute’s hard cap sits below the published guideline budget?

Then the institute’s figure governs, not the guideline. NIGMS’s own SBIR page states that applications exceeding the hard cap named in the specific notice of funding opportunity are not accepted unless an SBA-approved waiver topic applies. NIGMS also asks applicants whose budget approaches the cap to contact program staff at least six weeks before the deadline, which is enough lead time to rescope a work package rather than discover the ceiling after submission.

Kuv tus neeg muab peptide puas tuaj yeem sau npe ua lub koom haum tshawb fawb hauv STTR??

Only if the supplier is a qualifying research institution and the split holds. The SBIR/STTR Policy Directive teeb tsa qhov qis tshaj plaws ntawm STTR ntawm 40% ntawm R&D ua los ntawm lub lag luam me thiab 30% los ntawm ib lub koom haum tshawb fawb koom tes, nrog kev ua haujlwm subcontraction thib peb raug txwv ntawm 30%. Kev hloov pauv tsis raug tso cai vim tias qhov kev thov ntawd nyob hauv txoj cai ntawm 15 USC 638(e), yog li tus neeg muab khoom uas tsis tuaj yeem nqa txoj hauj lwm 30% yuav hloov cov qauv ntawm qhov khoom plig, tsis yog tsuas yog nyiaj txiag.

Kuv yuav tsum muab sijhawm ntev npaum li cas rau kev ua haujlwm tshuaj xyuas sab nraud hauv ib qho haujlwm Theem I??

Npaj qhov kev tshuaj xyuas kom tiav zoo hauv lub sijhawm muab khoom plig. NIH tus kheej kev tshuaj xyuas ntawm SBIR thiab STTR theem piav txog Theem I ntawm kev ua haujlwm uas khiav ntawm rau lub hlis rau rau mus txog ob xyoos, nrog qhov kawg luv luv sib xws. Kev sib xyaw, kev hloov kho thiab kev piav qhia yog raws li kev txiav txim, yog li kev piav qhia lig ua rau lub sijhawm tshuaj xyuas luv dua li kev tshawb fawb.

Xaus lus

Ib pob haujlwm sib haum xeeb tuaj yeem npaj txhij rau kev tshuaj xyuas yam tsis tau txais nyiaj pab. Kev ua tau zoo ntawm kev tshawb fawb, eligibility, program priorities, budget availability and the active notice determine the decision. Tie each milestone to an appropriate evidence plan and cost justification.

The next step is a document audit: for every milestone in your draft, confirm that a certificate of analysis, chromatogram, mass spectrum or method record exists or is scheduled in the funded period. Where one is missing, either the milestone moves to a later phase or the evidence moves into the current one. That check can expose unsupported readiness claims before submission, which is a reviewer finding a readiness claim the documents do not support.

Hais txog tus luam tawm. MOL Changes is a peptide research and development organisation that sells custom peptide synthesis, modification and production services, so it has a commercial interest in how outsourced peptide work is described. Weigh its perspective with that in mind; the guidance above does not depend on its services.

Zejun Peng

Chief Technology Officer; Peptide Synthesis Expert Kev txawj ntse tseem ceeb: Complex peptide synthesis, kev hloov amino acid uas tsis yog ntuj, and the construction of cyclic peptides and stapled peptides.

Hais txog tus sau Cov ntawv tshiab tshaj plaws

Biography:Zejun Peng has extensive experience in organic chemistry and peptide synthesis. He is proficient in the combined application of solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), and is particularly skilled at overcoming “extremely difficult-to-synthesize sequences” (such as ultra-long-chain peptides, highly hydrophobic sequences, and multiple disulfide bond folding). Under his leadership, the team has successfully overcome technical bottlenecks in several specialized modifications (such as N-methylation, PEGylation, and fluorescent labeling), maintaining a synthesis success rate of over 98%.

• Proteoform Metrics rau kev txheeb xyuas peptide: Ntawm kev huv ntawm sequence 2026年11月1日
• Retatrutide and the GLP-1 Grey Market: Why Peptide Identity Is Only the Starting Point 2026年10月31日
• Six Peptides Recommended: What the July 2026 Advisory Votes Mean for Evidence Readiness 2026年10月31日
• s $3 Billion Biotech Fund Signal: Where Peptide Platform Capabilities Fit in the Next Capital Cycle 2026年10月31日
• Lonza's 2026 Txoj kev npaj: Cov lus nug rau cov neeg yuav Peptide CDMO 2026年10月29日

Fact Checked & Editorial Guidelines

Our Fact Checking Process

Peb muab qhov tseeb thiab kev ncaj ncees rau peb cov ntsiab lus. Nov yog peb txoj kev khaws cia cov qauv siab:

1. Kev tshuaj xyuas los ntawm cov kws tshaj lij: Tag nrho cov ntawv raug tshuaj xyuas los ntawm cov kws tshaj lij hauv lub ntsiab lus.
2. Kev txheeb xyuas qhov chaw: Cov ntaub ntawv muaj kev ntseeg tau, cov chaw tshiab tshaj plaws.
3. Kev pom tseeb: Peb qhia meej txog cov ntaub ntawv thiab qhia txog tej kev tsis sib haum xeeb.

Tau tshuaj xyuas los ntawm: Cov kws tshaj lij hauv lub ntsiab lus

Peb Pawg Saib Xyuas

Peb cov ntsiab lus raug tshuaj xyuas zoo los ntawm cov kws tshaj lij muaj kev paub kom paub tseeb tias muaj tseeb thiab muaj feem xyuam.

• Cov kws tshaj lij muaj txuj ci: Txhua tsab ntawv raug tshuaj xyuas los ntawm cov kws tshaj lij uas muaj kev paub tshwj xeeb hauv thaj chaw.
• Cov ntaub ntawv tshiab tshaj plaws: Peb suav nrog cov kev tshawb fawb tshiab tshaj plaws, cov kev hloov tshiab, thiab cov qauv.
• Kev cog lus rau qhov zoo: Cov neeg tshuaj xyuas xyuas kom meej meej, kev raug, thiab tag nrho.

Nrhiav lub npe tshuaj xyuas los ntawm cov kws tshaj lij kom nyeem cov ntsiab lus uas koj tuaj yeem ntseeg tau.